» Articles » PMID: 36142722

Ionizing Radiation from Radiopharmaceuticals and the Human Gut Microbiota: An Ex Vivo Approach

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Sep 23
PMID 36142722
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to determine the effect of three widely used radiopharmaceuticals with intestinal excretion on selected relevant bacteria that are part of the human gut microbiota, using an ex vivo approach. Fecal samples obtained from healthy volunteers were analyzed. Each sample was divided into four smaller aliquots. One served as the non-irradiated control. The other three were homogenized with three radiopharmaceutical solutions ([I]NaI, [Tc]NaTcO, and [Ra]RaCl). Relative quantification of each taxa was determined by the 2 method, using the ribosomal gene 16S as an internal control (primers 534/385). Twelve fecal samples were analysed: three controls and nine irradiated. Our experiment showed fold changes in all analyzed taxa with all radiopharmaceuticals, but results were more significant with I-131, ranging from 1.87-83.58; whereas no relevant differences were found with Tc-99m and Ra-223, ranging from 0.98-1.58 and 0.83-1.97, respectively. This study corroborates limited existing research on how ionizing radiation changes the gut microbiota composition, providing novel data regarding the ex vivo effect of radiopharmaceuticals. Our findings justify the need for future larger scale projects.

Citing Articles

Gut Microbiota Is Not Significantly Altered by Radioiodine Therapy.

Barata P, Oliveira A, Soares R, Fernandes A Nutrients. 2025; 17(3).

PMID: 39940254 PMC: 11819986. DOI: 10.3390/nu17030395.


Early and long-term responses of intestinal microbiota and metabolites to I treatment in differentiated thyroid cancer patients.

Lu G, Gao D, Liu Y, Yu X, Jiang W, Lv Z BMC Med. 2024; 22(1):300.

PMID: 39020393 PMC: 11256643. DOI: 10.1186/s12916-024-03528-3.


Human Intestinal Organoids and Microphysiological Systems for Modeling Radiotoxicity and Assessing Radioprotective Agents.

Bouges E, Segers C, Leys N, Lebeer S, Zhang J, Mastroleo F Cancers (Basel). 2023; 15(24).

PMID: 38136404 PMC: 10741417. DOI: 10.3390/cancers15245859.


Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy.

Li W, Cheng F, Zhang J, Li C, Yu D, Simayijiang H Int J Gen Med. 2023; 16:4453-4464.

PMID: 37808207 PMC: 10557971. DOI: 10.2147/IJGM.S433433.


Editorial of Special Issues "Gut Microbiota-Host Interactions: From Symbiosis to Dysbiosis 2.0".

Zuccaro V, Ponziani F, Bruno R Int J Mol Sci. 2023; 24(10).

PMID: 37240323 PMC: 10219519. DOI: 10.3390/ijms24108977.

References
1.
Nam Y, Kim H, Seo J, Kang S, Bae J . Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS One. 2013; 8(12):e82659. PMC: 3867375. DOI: 10.1371/journal.pone.0082659. View

2.
Yi Y, Shen L, Shi W, Xia F, Zhang H, Wang Y . Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study. Clin Cancer Res. 2020; 27(5):1329-1340. DOI: 10.1158/1078-0432.CCR-20-3445. View

3.
Vanhoutte T, Huys G, Brandt E, Swings J . Temporal stability analysis of the microbiota in human feces by denaturing gradient gel electrophoresis using universal and group-specific 16S rRNA gene primers. FEMS Microbiol Ecol. 2009; 48(3):437-46. DOI: 10.1016/j.femsec.2004.03.001. View

4.
Andreyev H, Muls A, Norton C, Ralph C, Watson L, Shaw C . Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease. Frontline Gastroenterol. 2015; 6(1):53-72. PMC: 4283714. DOI: 10.1136/flgastro-2014-100468. View

5.
Flux G . Imaging and dosimetry for radium-223: the potential for personalized treatment. Br J Radiol. 2017; 90(1077):20160748. PMC: 5858794. DOI: 10.1259/bjr.20160748. View